Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Woehrer, A; Hackl, M; Waldhör, T; Weis, S; Pichler, J; Olschowski, A; Buchroithner, J; Maier, H; Stockhammer, G; Thomé, C; Haybaeck, J; Payer, F; von Campe, G; Kiefer, A; Würtz, F; Vince, GH; Sedivy, R; Oberndorfer, S; Marhold, F; Bordihn, K; Stiglbauer, W; Gruber-Mösenbacher, U; Bauer, R; Feichtinger, J; Reiner-Concin, A; Grisold, W; Marosi, C; Preusser, M; Dieckmann, K; Slavc, I; Gatterbauer, B; Widhalm, G; Haberler, C; Hainfellner, JA; Austrian Brain Tumour Registry.
Relative survival of patients with non-malignant central nervous system tumours: a descriptive study by the Austrian Brain Tumour Registry.
Br J Cancer. 2014; 110(2):286-296
Doi: 10.1038/bjc.2013.714
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Haybäck Johannes
- Payer Franz
- von Campe Gord
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Unlike malignant primary central nervous system (CNS) tumours outcome data on non-malignant CNS tumours are scarce. For patients diagnosed from 1996 to 2002 5-year relative survival of only 85.0% has been reported. We investigated this rate in a contemporary patient cohort to update information on survival. We followed a cohort of 3983 cases within the Austrian Brain Tumour Registry. All patients were newly diagnosed from 2005 to 2010 with a histologically confirmed non-malignant CNS tumour. Vital status, cause of death, and population life tables were obtained by 31 December 2011 to calculate relative survival. Overall 5-year relative survival was 96.1% (95% CI 95.1-97.1%), being significantly lower in tumours of borderline (90.2%, 87.2-92.7%) than benign behaviour (97.4%, 96.3-98.3%). Benign tumour survival ranged from 86.8 for neurofibroma to 99.7% for Schwannoma; for borderline tumours survival rates varied from 83.2 for haemangiopericytoma to 98.4% for myxopapillary ependymoma. Cause of death was directly attributed to the CNS tumour in 39.6%, followed by other cancer (20.4%) and cardiovascular disease (15.8%). The overall excess mortality in patients with non-malignant CNS tumours is 5.5%, indicating a significant improvement in survival over the last decade. Still, the remaining adverse impact on survival underpins the importance of systematic registration of these tumours.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Adult - epidemiology
- Central Nervous System Diseases - mortality
- Central Nervous System Diseases - pathology
- Female -
- Humans -
- Male -
- Middle Aged -
- Registries -
- Survival Rate -
- Young Adult -
- Find related publications in this database (Keywords)
- relative survival
- CNS tumour
- benign behaviour
- borderline behaviour
- non-malignant